Exclusive details on Cybin’s IND application with the FDA, a move that could make its CYB003 compound the first psilocybin analog to be evaluated in Phase 1/2a development.
Could This Novel Psychedelic Compound Treat Major Depressive Disorder? Clinical Trial Seeks To Find Out
